Top Page
JBM (Healthcare) Ltd.
(2161)
JBM (Healthcare) Ltd. (2161) vs. iShares MSCI Hong Kong ETF (EWH)
JBM (Healthcare) Ltd. Business Overview & Revenue Model
JBM (Healthcare) Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 782.29M | 782.29M | 648.41M | 520.32M | 406.14M | 397.16M |
| Gross Profit | 413.71M | 413.71M | 338.08M | 187.92M | 142.30M | 180.94M |
| EBITDA | 283.54M | 298.41M | 220.73M | 111.40M | 84.14M | 114.51M |
| Net Income | 197.26M | 197.26M | 130.46M | 57.09M | 24.62M | 22.60M |
Balance Sheet | ||||||
| Total Assets | 1.55B | 1.55B | 1.39B | 1.40B | 1.33B | 1.38B |
| Cash, Cash Equivalents and Short-Term Investments | 205.85M | 205.85M | 140.81M | 152.27M | 69.84M | 94.38M |
| Total Debt | 171.75M | 171.75M | 133.41M | 180.10M | 213.09M | 267.92M |
| Total Liabilities | 381.16M | 381.16M | 366.75M | 372.10M | 363.30M | 434.25M |
| Stockholders Equity | 1.08B | 1.08B | 970.68M | 985.51M | 929.20M | 904.71M |
Cash Flow | ||||||
| Free Cash Flow | 205.94M | 205.92M | 181.00M | 137.75M | 52.96M | 35.97M |
| Operating Cash Flow | 226.95M | 226.94M | 191.22M | 145.89M | 60.01M | 58.93M |
| Investing Cash Flow | -75.82M | -120.48M | 8.31M | -7.05M | -7.57M | -24.63M |
| Financing Cash Flow | -84.20M | -41.54M | -210.72M | -56.04M | -76.85M | -13.92M |
JBM (Healthcare) Ltd. Technical Analysis
JBM (Healthcare) Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$2.41B | 12.17 | 19.22% | 7.18% | 20.65% | 63.21% | |
73 Outperform | 1.82B | 9.55 | ― | 5.21% | 2.89% | -68.83% | |
72 Outperform | 2.79B | 9.70 | 12.26% | 4.11% | 7.43% | 21.88% | |
70 Outperform | 559.02M | 25.10 | ― | 7.58% | -1.99% | -81.52% | |
45 Neutral | 177.72M | -4.61 | -31.87% | ― | -17.32% | 55.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
JBM (Healthcare) Ltd. Corporate Events
JBM (Healthcare) Limited held its Annual General Meeting on July 28, 2025, where all proposed resolutions were passed with overwhelming support. Key decisions included the approval of financial statements, the declaration of a final dividend, the re-election of directors, and the reappointment of auditors. The meeting also authorized the board to manage directors’ remuneration and granted mandates for share repurchase and issuance, reflecting strong shareholder confidence and strategic positioning for future growth.
JBM (Healthcare) Limited has announced an update to its board of directors, detailing the roles and functions of each member effective from July 28, 2025. This announcement outlines the structure of the board and its committees, which include the Audit, Remuneration, Nomination, and Executive Committees. The update may impact the company’s governance and strategic direction, potentially influencing its operations and stakeholder relations.
JBM (Healthcare) Ltd. has revised the terms of reference for its Nomination Committee to enhance the process of identifying and evaluating candidates for its board of directors. This revision aims to improve board diversity and the effectiveness of the nomination process, potentially strengthening the company’s governance and stakeholder confidence.
JBM (Healthcare) Limited has announced the record dates for its upcoming Annual General Meeting and proposed final dividend. The company will close its register of members to determine shareholders’ eligibility to attend the meeting on July 28, 2025, and to receive the proposed final dividend on August 14, 2025. This announcement is significant for shareholders as it outlines the necessary steps to participate in the meeting and qualify for the dividend, reflecting the company’s commitment to shareholder engagement and financial distribution.
JBM (Healthcare) Limited announced the resignation of Mr. Wong Yat Wai, Patrick as an executive director and authorized representative, effective July 8, 2025, to concentrate on business development. Mr. Wong will continue as the CEO, while Mr. Yim Chun Leung has been appointed as the new authorized representative, signaling a strategic shift in the company’s leadership structure.
JBM (Healthcare) Limited has announced its upcoming Annual General Meeting, which will be conducted virtually on July 28, 2025. The meeting agenda includes approving the audited financial statements, declaring a final dividend of HK11.5 cents per share, re-electing directors, and authorizing the board to fix directors’ remuneration. Additionally, shareholders will vote on resolutions to grant the board mandates to repurchase shares and issue additional shares.
JBM (Healthcare) Ltd. has announced a discloseable transaction involving the acquisition of the entire issued share capital of a target company for HK$38,000,000. This acquisition, subject to certain conditions, is expected to enhance JBM’s market positioning by expanding its business operations, although it does not require shareholder approval under the Listing Rules.
JBM (Healthcare) Limited reported a significant financial performance for the year ended 31 March 2025, with a 20.7% increase in revenue to approximately HK$782.3 million and a 51.2% rise in profit attributable to equity shareholders to HK$197.3 million. The company also announced a substantial increase in dividends, reflecting its strong financial health and commitment to rewarding shareholders.
JBM (Healthcare) Limited has announced a final cash dividend of HKD 0.115 per share for the financial year ending 31 March 2025. The dividend will be paid on 28 August 2025, following shareholder approval on 28 July 2025. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders.
JBM (Healthcare) Limited has announced the re-designation of Mr. Sum Kwong Yip, Derek, and Mr. Yim Chun Leung from non-executive to executive directors, effective June 12, 2025. This move is expected to enhance the company’s strategic direction and operational management, leveraging the extensive experience of both individuals in the pharmaceutical and corporate finance fields.
JBM (Healthcare) Limited has announced a board meeting scheduled for June 12, 2025, to discuss and approve the company’s final results for the fiscal year ending March 31, 2025. The meeting will also consider the recommendation of a final dividend, highlighting potential financial implications for stakeholders.
JBM (Healthcare) Limited has announced a positive profit alert, expecting a significant increase in consolidated profit by at least 50% for the year ending March 31, 2025, compared to the previous year. This growth is attributed to strong sales performance driven by effective brand management and marketing strategies, highlighting the company’s successful positioning in the consumer healthcare market.